Atara Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Atara Biotherapeutics Inc ATRA.OQ reported quarterly adjusted earnings of 19 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.10. The mean expectation of four analysts for the quarter was for a loss of 46 cents per share. Wall Street expected results to range from -60 cents to -32 cents per share.

• Revenue fell 38.6% to $17.58 million from a year ago; analysts expected $7.35 million.

• Atara Biotherapeutics Inc's reported EPS for the quarter was 19 cents​.

• The company reported quarterly net income of $2.39 million.

• Atara Biotherapeutics Inc shares had risen by 41.9% this quarter and lost 17.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 66.7% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $17.00, about 35.6% above its last closing price of $10.96

This summary was machine generated from LSEG data August 11 at 08:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)